RecruitingNot ApplicableNCT05558345

Expression of Stress Markers During Meth Treatment (EXPRESS+)

Expression of Stress Markers in MSM Living With HIV Receiving Contingency Management for Methamphetamine Use Disorder


Sponsor

University of California, Los Angeles

Enrollment

55 participants

Start Date

Sep 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 45 Years

Inclusion Criteria18

  • For Contingency Management:
  • Assigned male sex at birth
  • to 45 years of age
  • Reports having sex with men in the past 12 months.
  • HIV-positive (confirmed by certification or by HIV rapid test)
  • Has an HIV care provider (last seen in the past 12 months)
  • Has a current antiretroviral prescription
  • Meets the DSM-5 criteria for methamphetamine use disorder using SCID-5
  • Urine test is positive for methamphetamine within 30 days of their screening visit
  • Seeking treatment for methamphetamine use disorder.
  • Ability to attend twice weekly appointments for drug testing and treatment
  • For Non-substance-using Control:
  • Assigned male sex at birth
  • to 45 years of age
  • Reports having sex with men in the past 12 months.
  • HIV-positive (confirmed by certification or by HIV rapid test)
  • Has an HIV care provider (last seen in the past 12 months)
  • Has a current antiretroviral prescription

Exclusion Criteria10

  • For Contingency Management:
  • Identifies as (cis- or transgender) female
  • Reports another current or past substance use disorder
  • Reports being in another intervention or clinical trial for substance use
  • Positive test for opioids, cocaine, and/or MDMA
  • For Non-substance-using Control:
  • Identifies as (cis- or transgender) female
  • Positive test for methamphetamine, opioids, cocaine, and/or MDMA.
  • Reports substance use (methamphetamine, opioids, cocaine, MDMA, hallucinogens, heavy alcohol use, and/or tobacco) in the past 6 months
  • Reports past or current substance use disorder

Interventions

BEHAVIORALContingency Management

A positive reinforcement behavioral treatment with escalating rewards for consecutive negative urine tests, starting at $10 and capped at a maximum of $40 per negative result.


Locations(1)

UCLA Vine Street Clinic

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05558345


Related Trials